Boehringer and Envisagenics to develop precision cancer therapies

​

Boehringer Ingelheim and Envisagenics have entered into a research collaboration and option agreement aimed at validating tumour-specific targets for the development of precision therapies in solid tumours.

The post Boehringer and Envisagenics to develop precision cancer therapies appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.